Overview

First Time Use of SD-809 in Huntington Disease

Status:
Completed
Trial end date:
2014-12-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether SD-809 tablets are effective in the treatment of chorea associated with Huntington's Disease.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Teva Pharmaceutical Industries